DK142171B - Fremgangsmåde til fremstilling af 15RS- eller 15SR-vinylderivater af prostaglandinforbindelser. - Google Patents
Fremgangsmåde til fremstilling af 15RS- eller 15SR-vinylderivater af prostaglandinforbindelser. Download PDFInfo
- Publication number
- DK142171B DK142171B DK279475AA DK279475A DK142171B DK 142171 B DK142171 B DK 142171B DK 279475A A DK279475A A DK 279475AA DK 279475 A DK279475 A DK 279475A DK 142171 B DK142171 B DK 142171B
- Authority
- DK
- Denmark
- Prior art keywords
- mixture
- hydroxy
- methyl ester
- acid methyl
- oxo
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 12
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 title description 5
- 238000002360 preparation method Methods 0.000 title description 3
- -1 Prostaglandin Compounds Chemical class 0.000 title description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 28
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 150000004702 methyl esters Chemical class 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 229920002554 vinyl polymer Polymers 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 101150058891 alc1 gene Proteins 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 229940046892 lead acetate Drugs 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000002901 organomagnesium compounds Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7421602A FR2275443A1 (fr) | 1974-06-21 | 1974-06-21 | Nouveau procede de preparation de derives substitues de l'acide prostanoique |
| FR7421602 | 1974-06-21 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK279475A DK279475A (es) | 1975-12-22 |
| DK142171B true DK142171B (da) | 1980-09-15 |
| DK142171C DK142171C (es) | 1981-02-09 |
Family
ID=9140359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK279475AA DK142171B (da) | 1974-06-21 | 1975-06-20 | Fremgangsmåde til fremstilling af 15RS- eller 15SR-vinylderivater af prostaglandinforbindelser. |
Country Status (17)
| Country | Link |
|---|---|
| JP (1) | JPS5113751A (es) |
| BE (1) | BE830475A (es) |
| CA (1) | CA1061338A (es) |
| CH (1) | CH596163A5 (es) |
| DD (1) | DD118412A5 (es) |
| DE (1) | DE2526355A1 (es) |
| DK (1) | DK142171B (es) |
| ES (1) | ES438725A1 (es) |
| FR (1) | FR2275443A1 (es) |
| GB (1) | GB1478262A (es) |
| IE (1) | IE41835B1 (es) |
| IL (1) | IL47437A (es) |
| LU (1) | LU72786A1 (es) |
| NL (1) | NL7507431A (es) |
| SE (1) | SE7505967L (es) |
| SU (1) | SU577977A3 (es) |
| ZA (1) | ZA753959B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4022912A (en) * | 1976-02-09 | 1977-05-10 | Miles Laboratories, Inc. | Use of 1-decarboxy-1-hydroxymethyl-PGE1 in therapeutic bronchodilation |
| JPH06104644B2 (ja) * | 1986-03-04 | 1994-12-21 | 住友化学工業株式会社 | 光学活性なシクロペンテノン誘導体の製造法 |
-
1974
- 1974-06-21 FR FR7421602A patent/FR2275443A1/fr active Granted
-
1975
- 1975-05-26 SE SE7505967A patent/SE7505967L/ not_active Application Discontinuation
- 1975-06-06 IL IL47437A patent/IL47437A/xx unknown
- 1975-06-12 DE DE19752526355 patent/DE2526355A1/de not_active Withdrawn
- 1975-06-19 DD DD186765A patent/DD118412A5/xx unknown
- 1975-06-20 LU LU72786A patent/LU72786A1/xx unknown
- 1975-06-20 CA CA229,850A patent/CA1061338A/fr not_active Expired
- 1975-06-20 ES ES438725A patent/ES438725A1/es not_active Expired
- 1975-06-20 CH CH808275A patent/CH596163A5/xx not_active IP Right Cessation
- 1975-06-20 IE IE1383/75A patent/IE41835B1/en unknown
- 1975-06-20 BE BE157537A patent/BE830475A/xx unknown
- 1975-06-20 ZA ZA3959A patent/ZA753959B/xx unknown
- 1975-06-20 NL NL7507431A patent/NL7507431A/xx not_active Application Discontinuation
- 1975-06-20 JP JP50074560A patent/JPS5113751A/ja active Pending
- 1975-06-20 SU SU7502145918A patent/SU577977A3/ru active
- 1975-06-20 DK DK279475AA patent/DK142171B/da not_active IP Right Cessation
- 1975-06-23 GB GB2659175A patent/GB1478262A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| ES438725A1 (es) | 1977-03-16 |
| CH596163A5 (es) | 1978-02-28 |
| JPS5113751A (es) | 1976-02-03 |
| NL7507431A (nl) | 1975-12-23 |
| IE41835B1 (en) | 1980-04-09 |
| FR2275443A1 (fr) | 1976-01-16 |
| CA1061338A (fr) | 1979-08-28 |
| BE830475A (fr) | 1975-12-22 |
| SU577977A3 (ru) | 1977-10-25 |
| DK142171C (es) | 1981-02-09 |
| DD118412A5 (es) | 1976-03-05 |
| ZA753959B (en) | 1977-01-26 |
| DK279475A (es) | 1975-12-22 |
| IL47437A (en) | 1979-10-31 |
| AU8211175A (en) | 1976-12-16 |
| FR2275443B1 (es) | 1976-10-22 |
| DE2526355A1 (de) | 1976-01-08 |
| LU72786A1 (es) | 1976-04-13 |
| GB1478262A (en) | 1977-06-29 |
| IL47437A0 (en) | 1975-08-31 |
| IE41835L (en) | 1975-12-21 |
| SE7505967L (sv) | 1975-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1277893A3 (ru) | Способ получени производных 4-фенил-1,3-диоксан-цис-5-илалкеновой кислоты или их оптически активных форм,или их физиологически приемлемых солей с основани ми | |
| DK149345B (da) | Fremgangsmaade til fremstilling af d,l-vincamin eller d,l-isovincamin eller de optiske antipoder deraf | |
| US6040308A (en) | Chroman derivatives | |
| CZ287168B6 (en) | Process for preparing 13,14-dihydro-15(R)-17-phenyl-18,19,20-trinor-PGF2 esters and intermediates for this preparation process | |
| Bartlett | Synthesis of. beta.-acylacrylic esters and. alpha.,. beta.-butenolides via. beta.-keto sulfoxide alkylation | |
| Manchand et al. | Synthesis of vitamin A via sulfones: A C15 sulfone route | |
| Shulgin et al. | Psychotomimetic phenylisopropylamines. 5. 4-Alkyl-2, 5-dimethoxyphenylisopropylamines | |
| SU479290A3 (ru) | Способ получени 2-(фурилметил)-6,7бензоморфанов | |
| DK142171B (da) | Fremgangsmåde til fremstilling af 15RS- eller 15SR-vinylderivater af prostaglandinforbindelser. | |
| Ojima et al. | Syntheses and properties of dimethylbisdehydro [15] annulenone,-[17] annulenone,-[19] annulenone, and-[21] annulenone | |
| JPH03173880A (ja) | 新規な置換テトラヒドロフラン誘導体 | |
| US4334969A (en) | Photochemical process for the synthesis of strobilurin | |
| Buese et al. | Oligomerization of vinyl monomers. 17. Stereoselective methylation of 1-lithio-1, 3-bis (phenylsulfinyl) butane. Kinetic vs. thermodynamic control in the formation of diastereomeric ion pairs | |
| US2705728A (en) | Process for the preparation of unsaturated alicyclic 2-methylbutanal compounds | |
| US3712928A (en) | Phenylcyclohexane derivatives and methods for their manufacture | |
| US3991061A (en) | Azanaphthaleneacetic acid derivatives | |
| US4124642A (en) | 6,6,7-Trimethyl-tricyclo[5.2.2.01,5 ]undec-8-en-2-one | |
| Kanaoka et al. | Photocyclization of benzofurancarboxanilides. Photorearrangement of the benzodihydrofuran system to 3-o-hydroxyphenylquinolones | |
| US3042689A (en) | 16-hydrocarbon substituted 16,17-dihydroxyestren-3-ones, their esters and ethers, and intermediates for their production | |
| US4353906A (en) | Chromanol derivatives and their use for treating hypertension | |
| US2545434A (en) | 3-nitro-4-amino-thiophanes | |
| SU494028A1 (ru) | Способ получени 3 @ -аминоизоксазолиновых производных стероидов | |
| JPS596311B2 (ja) | セスキテルペン誘導体の製造法 | |
| US2422625A (en) | Processes for the production of chromanes | |
| Angyal et al. | Steric Effects on the Iodide-Induced Elimination of 2-and 3-Methanesulfonyloxy Groups from 5α-Cholestane Derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PBP | Patent lapsed |